JARO Biosciences is a company affiliated with VIVO Ventures, a venture capital firm that specializes in investments in biopharmaceutical companies. JARO Biosciences was established in 2007 and is focusing its efforts on the creation of new businesses in China by combining its entrepreneurial activities with the venture capital experience and capabilities of the VIVO team.

JARO Biosciences was founded by James Huang and Roberto Cetrullo, with the purpose of creating new businesses through the in-licensing, development and commercialization of biopharmaceuticals.

James Huang and Roberto Cetrullo are veterans of the pharmaceutical industry who offer more than four decades of global commercial management and corporate development experience with leading multinational pharmaceutical companies and small to mid-sized biotechnology companies. 

JARO collaborates with a vast network of world class professionals and leading pharmaceutical and biotechnology companies in China, North America, Europe and Japan. It performs due diligence on a broad range of potential Chinese partners with strong therapeutic area expertise, and it is currently engaged in the negotiation of multiple in-licensing and partnership collaborations.